Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PREDNISOLONE ACETATE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (S01B, S01BA) — coverage varies; not interchangeable

  • Dexamethasone (Maxidex): general benefit
  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Ketorolac tromethamine (Acular): general benefit
  • Bromfenac (Prolensa): not a benefit

Ratio-Prednisolone · DIN 00700401 · 1% · Oph suspension

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Prednisolone · DIN 00700401 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-04-20 · brand TEVA-PREDNISOLONE · ATC S01BA04 PREDNISOLONE · form Suspension · route Ophthalmic · ingredients PREDNISOLONE ACETATE 1 % · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ratio-Prednisolone: Formulary list price $1.9400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.9400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7042 · Verify on the e-Formulary ↗ (DIN 00700401)

Source record
DIN 00700401: Ratio-Prednisolone Raw flags: sec3=Y Item: 520800017; group id 600; item number 1560; lccId None; manufacturer id RPH Source form: Oph Susp; strength: 1% Recorded listing: General benefit Source prices (unrounded): $1.9400; ministry $1.9400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00700401 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7042
Interchangeable products
Pred Forte · DIN 00301175 · not recorded
Shortage status: resolved shortage (ended 2026-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00700401
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pred Forte · DIN 00301175 · 1% · Oph suspension

Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pred Forte · DIN 00301175 Manufacturer: Allergan Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-09-25 · brand PRED FORTE · ATC S01BA04 PREDNISOLONE · form Suspension · route Ophthalmic · ingredients PREDNISOLONE ACETATE 1 %/W/V · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Pred Forte: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1937 · Verify on the e-Formulary ↗ (DIN 00301175)

Source record
DIN 00301175: Pred Forte Raw flags: notABenefit=Y, sec3=Y Item: 520800017; group id 600; item number 1560; lccId None; manufacturer id ALL Source form: Oph Susp; strength: 1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00301175 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1937
Interchangeable products
Ratio-Prednisolone · DIN 00700401 · $1.9400
Shortage status: resolved shortage (ended 2023-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00301175
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PREDNISOLONE SODIUM PHOSPHATE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (S01B, S01BA) — coverage varies; not interchangeable

  • Dexamethasone (Maxidex): general benefit
  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Ketorolac tromethamine (Acular): general benefit
  • Bromfenac (Prolensa): not a benefit

PMS-Prednisolone · DIN 02245532 · 6.7mg/5mL · oral liquid

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Prednisolone · DIN 02245532 Manufacturer: Pharmascience Inc.; listing date 2004-07-20 Health Canada: Marketed since 2002-03-19 · brand PMS-PREDNISOLONE · ATC H02AB06 PREDNISOLONE · form Solution · route Oral · ingredients PREDNISOLONE (PREDNISOLONE SODIUM PHOSPHATE) 5 MG/5ML · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Prednisolone: Formulary list price $0.1259/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1259 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69619 · Verify on the e-Formulary ↗ (DIN 02245532)

Source record
DIN 02245532: PMS-Prednisolone Raw flags: sec3=Y Item: 680400071; group id 718; item number 1774; lccId None; manufacturer id PMS Source form: O/L; strength: 6.7mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1259; ministry $0.1259 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245532 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69619
Interchangeable products
Pediapred Oral Liquid · DIN 02230619 · not recorded
Shortage status: resolved shortage (ended 2022-12-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245532
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pediapred Oral Liquid · DIN 02230619 · 6.7mg/5mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-22 — choose a marketed DIN from the same-category list.Discontinued 2024-07-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-07-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pediapred Oral Liquid · DIN 02230619 Manufacturer: Sanofi Aventis Pharma; listing date 2003-01-30 Health Canada: Cancelled post market since 2024-07-22 · brand PEDIAPRED · ATC H02AB06 PREDNISOLONE · form Solution · route Oral · ingredients PREDNISOLONE (PREDNISOLONE SODIUM PHOSPHATE) 5 MG/5ML · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Pediapred Oral Liquid: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49795 · Verify on the e-Formulary ↗ (DIN 02230619)

Source record
DIN 02230619: Pediapred Oral Liquid Raw flags: notABenefit=Y, sec3=Y Item: 680400071; group id 718; item number 1774; lccId None; manufacturer id SAV Source form: O/L; strength: 6.7mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230619 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49795
Interchangeable products
PMS-Prednisolone · DIN 02245532 · $0.1259
Shortage status: discontinued (2023-12-18, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230619
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-07-22 — choose a marketed DIN from the same-category list.

METHYLPREDNISOLONE ACETATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (S01B, S01BA) — coverage varies; not interchangeable

  • Dexamethasone (Maxidex): general benefit
  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Ketorolac tromethamine (Acular): general benefit
  • Bromfenac (Prolensa): not a benefit

Depo-Medrol · DIN 00030759 · 40mg/mL · injection suspension-1mL Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Medrol · DIN 00030759 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2004-01-08 · brand DEPO-MEDROL · ATC H02AB04 METHYLPREDNISOLONE · form Suspension · route Intramuscular, Intrasynovial, Intralesional, Intra-articular · ingredients METHYLPREDNISOLONE ACETATE 40 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Medrol: Formulary list price $6.8762/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8762 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1134 · Verify on the e-Formulary ↗ (DIN 00030759)

Source record
DIN 00030759: Depo-Medrol Raw flags: sec3=Y Item: 680400025; group id 716; item number 1768; lccId None; manufacturer id PFI Source form: Inj Susp-1mL Pk; strength: 40mg/mL Recorded listing: General benefit Source prices (unrounded): $6.8762; ministry $6.8762 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030759 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1134
Shortage status: anticipated shortage (last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030759
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Depo-Medrol · DIN 00030767 · 80mg/mL · injection suspension-1mL Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Medrol · DIN 00030767 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2004-03-16 · brand DEPO-MEDROL · ATC H02AB04 METHYLPREDNISOLONE · form Suspension · route Intrasynovial, Intra-articular, Intralesional, Intramuscular · ingredients METHYLPREDNISOLONE ACETATE 80 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Medrol: Formulary list price $13.1816/unit (unit not stated in source; not the patient's cost)

Ministry pays: $13.1816 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=789 · Verify on the e-Formulary ↗ (DIN 00030767)

Source record
DIN 00030767: Depo-Medrol Raw flags: sec3=Y Item: 680400024; group id 716; item number 1769; lccId None; manufacturer id PFI Source form: Inj Susp-1mL Pk; strength: 80mg/mL Recorded listing: General benefit Source prices (unrounded): $13.1816; ministry $13.1816 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030767 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=789
Shortage status: resolved shortage (ended 2026-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030767
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Depo-Medrol · DIN 01934325 · 100mg/5mL · injection suspension-5mL Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Medrol · DIN 01934325 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-05-03 · brand DEPO-MEDROL · ATC H02AB04 METHYLPREDNISOLONE · form Suspension · route Intrasynovial, Intra-articular, Intramuscular, Intralesional · ingredients METHYLPREDNISOLONE ACETATE 20 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Medrol: Formulary list price $15.3767/unit (unit not stated in source; not the patient's cost)

Ministry pays: $15.3767 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18988 · Verify on the e-Formulary ↗ (DIN 01934325)

Source record
DIN 01934325: Depo-Medrol Raw flags: sec3=Y Item: 680400026; group id 716; item number 1770; lccId None; manufacturer id PFI Source form: Inj Susp-5mL Pk; strength: 100mg/5mL Recorded listing: General benefit Source prices (unrounded): $15.3767; ministry $15.3767 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01934325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18988
Shortage status: resolved shortage (ended 2025-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01934325
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE 52:08 Anti-Inflammatory Agents

DEXAMETHASONE

· 2 products · General benefit · strengths: 0.1% · Oph Oint-3.5g Pk, Oph Susp

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

KETOROLAC TROMETHAMINE

· 3 products · General benefit · strengths: 0.5%, 0.45% w/v · Oph Sol, Oph Sol-0.4mL Vial Pk (Preservative-Free)

BROMFENAC

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.07% w/v · Oph Sol (With Preservative)

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

MOMETASONE FUROATE

· 3 products · General benefit · strengths: 400mcg/Metered Dose, 200mcg/Metered Dose · Pd Inh-30 Dose Pk, Pd Inh-60 Dose Pk

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 4 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS PRED FORTE® (prednisolone acetate) is indicated for: • the treatment of steroid‐responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics No overall differences in safety or effectiveness have been observed in elderly patients https://pdf.hres.ca/dpd_pm/00074796.PDF PM date: FEB 28, 2024 Source product: PRED FORTE; DIN 00301175; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS Management of conditions known to be responsive to prednisone or prednisolone where anti-inflammatory action or immunosuppression or adrenocortical supplementation and replacement is required. For most indications, glucocorticoid administration provides symptomatic relief, but has no effect on the underlying disease processes. Use of these medications does not eliminate the need for other therapies that may be required. 1.1 Pediatrics pms-PREDNISOLONE oral solution is appropriate for pediatric usage and for those patients with difficulty swallowing solid oral dosage forms. https://pdf.hres.ca/dpd_pm/00075127.PDF PM date: MAR 28, 2024 Source product: PMS-PREDNISOLONE; DIN 02245532; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. INDICATIONS DEPO-MEDROL (methylprednisolone acetate) is indicated for: A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL (methylprednisolone acetate) is indicated as follows: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice, synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. https://pdf.hres.ca/dpd_pm/00080840.PDF PM date: 2025-06-19 Source product: DEPO-MEDROL; DIN 00030759; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Pediapred Oral Liquid · DIN 02230619 Shortage status: discontinued (2023-12-18, reported by SANOFI-AVENTIS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230619

Check this DIN again

Other review policies

For Pred Forte, Pediapred Oral Liquid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026